OREGA enters into a License Agreement with Genmab
6 December 2022
IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE
24 February 2023
The OREGA Biotech team wishes you all a wonderful holiday season, a Merry Christmas and a healthy and successful new year !
